IL6 and rheumatoid arthritis: Structural optimization of these analogs identified key features (e.g., flexible alkyl chains) necessary for efficacy, with lead compounds demonstrating reduced IL-6 secretion in rheumatoid arthritis models and improved CNS repair in EAE (9, 58).